Home » Topics » Regulatory » EMA

EMA
RSS

Cytovir ADV ready to receive orphan drug designation in Europe

Jan. 8, 2014

CHMP gives positive opinion on subcutaneous tocilizumab

Dec. 27, 2013

EMA accepts tolvaptan MAA for ADPKD

Dec. 27, 2013

EMA accepts dalbavancin MAA for review

Dec. 24, 2013

EMA accepts filing of MAA for cangrelor

Dec. 24, 2013

Cometriq receives positive CHMP opinion for thyroid carcinoma

Dec. 23, 2013

MultiStem receives orphan drug designation in Europe

Dec. 18, 2013

EMA accepts Fibrocaps MAA for review

Nov. 29, 2013

EMA grants accelerated assessment to faldaprevir

Nov. 27, 2013

Celgene receives positive CHMP opinion for Abraxane in combination with gemcitabine

Nov. 26, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 17, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...